CN103599323A - Traditional Chinese medicinal composition for treating prostatitis - Google Patents
Traditional Chinese medicinal composition for treating prostatitis Download PDFInfo
- Publication number
- CN103599323A CN103599323A CN201310569659.4A CN201310569659A CN103599323A CN 103599323 A CN103599323 A CN 103599323A CN 201310569659 A CN201310569659 A CN 201310569659A CN 103599323 A CN103599323 A CN 103599323A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- radix
- preparation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, relates to a traditional Chinese medicinal composition for treating prostatitis, and the traditional Chinese medicinal composition for treating prostatitis is provided for overcoming the defect in the prior art and reducing pains of patients with prostatitis. The traditional Chinese medicinal composition has remarkable anti-inflammation pain-relieving activity, is remarkable in curative effect, safe and reliable, and has wide clinical application prospect.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of prostatitic Chinese medicine composition and medical usage thereof for the treatment of.
Background technology
Chronic prostatitis (chronic prostatitis, CP) is a kind of intractable Urology Surgery common disease, and its course of disease is easily delayed recurrence, obviously affects patient's quality of life, and may cause serious impact to its spouse's healthy reproduction.Chronic prostatitis belongs to the category of " stranguria ", " difficulty in urination " in Chinese medicine, its origin cause of formation is often by retention of damp-heat in the interior, and retardance mechanism of qi, with the passing of time becomes the stasis of blood, undermines due to kidney yang, kidney yin.Therefore also can be according to the difference of clinical syndrome differentiation to its treatment, and take the method for clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling or the kidney invigorating and essence nourishing.Special due on prostate anatomical position, conventional route of administration as oral or vein and operative treatment curative effect all not very good.
The traditional Chinese medical science thinks that its cause of disease one is for having a liking for food cigarette, wine, pungent, delicious food savoury, impairing the spleen and stomach, and wine is raw damp and hot, the multiple abscess part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels; Two is intemperate sexual intercourse, directly contamination, and damp and hot poison is evil to drive in the wrong direction, and stations the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels; Three is the impacts such as society and environmental factors, medium stimulation, and libido can not get normal catharsis, frequent masturbation, and intemperate sexual intercourse, bears essence not let out, and causes prostate repeatedly congested, and retention of corruptive essence essence chamber accumulates wine poison of a specified duration, hinders in meridians; Or feelings will is not smooth, depressed rage impairing the liver, irritability is lost in catharsis, hematogenous blockage and cause coagulation of QI-blood for a long time, coagulation of QI-blood can increase the weight of again that damp and hot poison is evil to be formed, both reciprocal causations.The symptom of chronic prostatitis varies with each individual, and is mainly divided into following two kinds: a kind of for pain symptom, containing around hypogastric region, lumbosacral region, anus, the position pain such as perineal position and testis, penis; Another kind is the discomfort of urinating, and it is white etc. that as unable in urine retention, frequent micturition, urgent micturition, urine, urine drips.General Symptoms is mainly that anxiety, energy are not concentrated, lassitude, also can be attended by sexual function abnormal, as ejaculate too fast, erection is not hard, hyposexuality etc.NIH (NIH) is divided into Four types I, acute bacterial prostatitis by prostatitis, II, chronic bacterial prostatitis, III, chronic nonbacterial prostatitis, IV, the struvite prostatitis of silent.Wherein III type is divided into two hypotypes according to prostatic fluid (EPS) microscopy, WBC (leukocyte) 10/HP is a type above, following and the pH value of WBC10/HP is lower is b type, i.e. chronic nonbacterial prostatitis/Pelvic pain syndrome (CAP/CPPS).
Primary treatment method for chronic prostatitis is Drug therapy and naturopathy at present, wherein Drug therapy comprises each antibiotics, α receptor blocking agent, immunosuppressant and supplementary zinc and vitamin, and route of administration is for oral administration, injection, rectal perfusion, anus filling, body of gland injection etc.; Wherein naturopathy comprises microwave, muscle electric stimulation, hot water hip-bath, massage of prostate, the four cavities conduit pipe administrations of two capsule, direct injection (per rectum or perineum), medicine iontophoresis.Primary disease also causes very large psychological problems, also comprises Mental Intervention in Treatment in current Therapeutic Method, mainly take psychological counseling as main.But adopt above-mentioned Therapeutic Method, patient is comparatively painful, and the treatment persistent period is longer, and effect is not ideal.Various ways above, damage testicular spermatogenic, it is only auxiliary treatment means, certain methods complicated operation even, and problems such as dangerous, cross infection in addition, the suppository of other rectals, unguentum exist that dosage form is unreasonable, compatibility not science, the poor drawback of therapeutic effect.
Summary of the invention
In order to make up the deficiencies in the prior art, alleviate the misery of prostatitis patient, the invention provides a kind of prostatitic Chinese medicine composition for the treatment of, it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
Treat a prostatitic Chinese medicine composition, this Chinese medicine composition is made by the raw material of following weight portion: Rhizoma Corydalis 10-12 part, Cortex Cinnamomi 5-8 part, Herba Epimedii 6-9 part, Rhizoma dioscoreae 3-5 part, Radix Achyranthis Bidentatae 10-12 part, Semen Cuscutae 10-12 part, Radix Polygalae 3-5 part, Pericarpium Citri Reticulatae 3-5 part, Radix Salviae Miltiorrhizae 10-12 part, Flos Lonicerae 8-10 part, Rhizoma Polygoni Cuspidati 6-9 part, Polyalthia nemoralis A. D C. 10-12 part, Radix Angelicae Dahuricae 10-12 part, Radix Codonopsis 10-12 part, Rhizoma Cyperi 12-15 part, Radix Et Caulis Acanthopanacis Senticosi 9-12 part.
In Chinese medicine composition described above, can also contain Radix Glycyrrhizae 5-8 part and Fructus Ligustri Lucidi 12-15 part.These two kinds of Chinese medicines can further strengthen the anti-inflammatory pain-stopping effect of the above-mentioned Chinese medicine composition of the present invention.
The present invention also asks for protection the purposes of above-mentioned Chinese medicine composition in preparation treatment prostatitis medicine.Pharmaceutical composition of the present invention, when treatment prostatitis, demonstrates remarkable anti-inflammatory and antalgic activity.Drug effect embodiment 7 of the present invention shows, give positive drug and Chinese medicine composition of the present invention all can be obtained significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have utmost point significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group will significantly be better than positive controls.Drug effect embodiment 8 mices of the present invention lick foot response latency time showing, with model group comparison, after administration 1h and 2h, all be greater than model group the incubation period that the mice of each administration group of Chinese medicine composition of the present invention is added foot reaction, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate that this Chinese medicine composition of the present invention can extend adding the sufficient response latency that mice stimulates hot plate, has certain analgesic activity.Under same experiment condition, positive control drug has also extended the incubation period that mice is added foot reaction, has certain analgesic activity, but its analgesic effect and model group there was no significant difference.
In order to express better Chinese medicine composition of the present invention, Chinese medicine composition of the present invention can be prepared into conventional clinically dosage form.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention is prepared into powder, water preparation, tablet or capsule according to conventional preparation technology.
The present invention also provides a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, according to 4～9 times of coarse powder gross weight, adding volumetric concentration is 40%～95% alcoholic solution, reflux, extract, three times, return time is 2～5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
Chinese medicine composition of the present invention, aspect treatment prostatitis, compared with prior art has following advantage:
1) compare with the chemotherapeutic agent of current treatment, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and has improved patient's quality of life.
2) in Chinese medicine composition of the present invention, contain multi-medicament component, action target spot is numerous, has improved patient to the acceptance of medicine and compliance.
The specific embodiment
By specific embodiment, further describe the present invention below, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
one) FORMULATION EXAMPLE part
embodiment 1 Chinese medicine composition of the present invention and preparation method
The weight portion of Chinese medicinal components: Rhizoma Corydalis 10, Cortex Cinnamomi 5, Herba Epimedii 6, Rhizoma dioscoreae 3, Radix Achyranthis Bidentatae 10, Semen Cuscutae 10, Radix Polygalae 3, Pericarpium Citri Reticulatae 3, Radix Salviae Miltiorrhizae 10, Flos Lonicerae 8, Rhizoma Polygoni Cuspidati 6, Polyalthia nemoralis A. D C. 10, the Radix Angelicae Dahuricae 10, Radix Codonopsis 10, Rhizoma Cyperi 12, Radix Et Caulis Acanthopanacis Senticosi 9.
Preparation method: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, adding volumetric concentration according to 4～9 times of coarse powder gross weight is 40%～95% alcoholic solution, reflux, extract, three times, return time is 2～5h, filters filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
embodiment 2 Chinese medicine composition of the present invention and preparation method
The weight portion of Chinese medicinal components: Rhizoma Corydalis 12, Cortex Cinnamomi 8, Herba Epimedii 9, Rhizoma dioscoreae 5, Radix Achyranthis Bidentatae 12, Semen Cuscutae 12, Radix Polygalae 5, Pericarpium Citri Reticulatae 5, Radix Salviae Miltiorrhizae 12, Flos Lonicerae 10, Rhizoma Polygoni Cuspidati 9, Polyalthia nemoralis A. D C. 12, the Radix Angelicae Dahuricae 12, Radix Codonopsis 12, Rhizoma Cyperi 15, Radix Et Caulis Acanthopanacis Senticosi 12.
Preparation method is with embodiment 1.
embodiment 3 Chinese medicine composition of the present invention and preparation method
The weight portion of Chinese medicinal components: Rhizoma Corydalis 11, Cortex Cinnamomi 7, Herba Epimedii 7, Rhizoma dioscoreae 4, Radix Achyranthis Bidentatae 11, Semen Cuscutae 11, Radix Polygalae 4, Pericarpium Citri Reticulatae 4, Radix Salviae Miltiorrhizae 11, Flos Lonicerae 9, Rhizoma Polygoni Cuspidati 8, Polyalthia nemoralis A. D C. 11, the Radix Angelicae Dahuricae 11, Radix Codonopsis 11, Rhizoma Cyperi 13, Radix Et Caulis Acanthopanacis Senticosi 10.
Preparation method is with embodiment 1.
embodiment 4 Chinese medicine composition of the present invention and preparation method
The weight portion of Chinese medicinal components: 13 parts of Rhizoma Corydalis 10, Cortex Cinnamomi 5, Herba Epimedii 6, Rhizoma dioscoreae 3, Radix Achyranthis Bidentatae 10, Semen Cuscutae 10, Radix Polygalae 3, Pericarpium Citri Reticulatae 3, Radix Salviae Miltiorrhizae 10, Flos Lonicerae 8, Rhizoma Polygoni Cuspidati 6, Polyalthia nemoralis A. D C. 10, the Radix Angelicae Dahuricae 10, Radix Codonopsis 10, Rhizoma Cyperi 12, Radix Et Caulis Acanthopanacis Senticosi 9, Radix Glycyrrhizae 5, Fructus Ligustri Lucidi
Preparation method is with embodiment 1.
embodiment 5 Chinese medicine composition of the present invention and preparation method
The weight portion of Chinese medicinal components: Rhizoma Corydalis 12, Cortex Cinnamomi 8, Herba Epimedii 9, Rhizoma dioscoreae 5, Radix Achyranthis Bidentatae 12, Semen Cuscutae 12, Radix Polygalae 5, Pericarpium Citri Reticulatae 5, Radix Salviae Miltiorrhizae 12, Flos Lonicerae 10, Rhizoma Polygoni Cuspidati 9, Polyalthia nemoralis A. D C. 12, the Radix Angelicae Dahuricae 12, Radix Codonopsis 12, Rhizoma Cyperi 15, Radix Et Caulis Acanthopanacis Senticosi 12,8 parts, Radix Glycyrrhizae, Fructus Ligustri Lucidi 12.
Preparation method is with embodiment 1.
embodiment 6 Chinese medicine composition of the present invention and preparation method
The weight portion of Chinese medicinal components: Rhizoma Corydalis 11, Cortex Cinnamomi 7, Herba Epimedii 7, Rhizoma dioscoreae 4, Radix Achyranthis Bidentatae 11, Semen Cuscutae 11, Radix Polygalae 4, Pericarpium Citri Reticulatae 4, Radix Salviae Miltiorrhizae 11, Flos Lonicerae 9, Rhizoma Polygoni Cuspidati 8, Polyalthia nemoralis A. D C. 11, the Radix Angelicae Dahuricae 11, Radix Codonopsis 11, Rhizoma Cyperi 13, Radix Et Caulis Acanthopanacis Senticosi 10,6 parts, Radix Glycyrrhizae, Fructus Ligustri Lucidi 15.
Preparation method is with embodiment 1.
(2) drug effect embodiment part
the antiinflammatory action of embodiment 7 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone has stronger anti-inflammatory activity, that synthetic is also naturally occurring glucocorticoid, hydrocortisone enters after cell, activate cytoplasmic receptor, after allosteric, enter nucleus, be combined with DNA response element, cause inhibition or the induction of genetic transcription, the expression of inflammation associated protein is changed.
, experimental technique:
50 KM mices, male and female half and half, body weight 25-30 gram, by body weight, be divided at random 5 groups, i.e. dosage group in model control group, compositions high dose group, compositions, compositions low dose group, positive controls, every group 10, each administration group mice gives respectively following medicine:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Compositions high dose group: gavage gives 50mg/kg embodiment 1 Chinese medicine composition Chinese medicine composition by crude drug amount;
Dosage group in compositions: gavage gives 20 mg/kg embodiment 1 Chinese medicine compositions, and Chinese medicine composition is by crude drug amount;
Compositions low dose group: gavage gives 5 mg/kg embodiment 1 Chinese medicine compositions, and Chinese medicine composition is by crude drug amount;
Each administration group is administered once every day, successive administration 7d.After last administration, get dimethylbenzene 20 μ l, be applied to each mouse right ear.After 30 minutes, get and be respectively subject to reagent 0.03 ml to be evenly applied to respectively mouse right ear, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures and respectively organizes the mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, and the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
, experimental result:
Measure each experimental mice ear method of double differences and evaluate the antiphlogistic effects of each medication group medicine.Measurement result is in Table 1.
Each experimental mice ear method of double differences comparison of table 1
With model control group comparison,
* p< 0.05; With model control group comparison,
* p< 0.01;
With positive controls comparison,
# p< 0.05; With positive controls comparison,
## p< 0.01.
Result demonstration gives positive drug and Chinese medicine composition of the present invention all can be obtained significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have utmost point significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group will significantly be better than positive controls.
the impact of embodiment 8 Chinese medicine composition of the present invention on mice hot-plate analgesia
1 mice hot plate pain model is made
Body weight 20g left and right female mice is placed on hot plate dolorimeter, screen 90 of qualified ♀ mices and (lick metapedes time < 5 s or > 30 s throw aside, for preventing foot, scald, also should establish deadline, be generally 60s), be the threshold of pain index incubation period that the mice of take is added metapedes reaction, get 72 jennies, be divided into 6 groups, 12/group, it is model group, cydiodine, Rhizoma dioscoreae supernatant sheet group, Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 1) low dose group, middle dosage group and high dose group.Each group is gastric infusion, and 1 times/day, dosage is as shown in table 10, after successive administration 14d, and the time that after mensuration last medicine, 60 min, 120 min add foot reaction.
2 Chinese medicine compositions of the present invention are on licking the impact of foot response latency in the experiment of mice hot-plate analgesia
Mice licks foot response latency time showing, with model group comparison, after administration after 1h and 2h, be all greater than model group the incubation period that the mice of each administration group of Chinese medicine composition of the present invention is added foot reaction, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate that this Chinese medicine composition of the present invention can extend adding the sufficient response latency that mice stimulates hot plate, has certain analgesic activity.Under same experiment condition, positive control drug cydiodine group (
p< 0.05) and Rhizoma dioscoreae supernatant sheet group (1h,
p< 0.05; 2h,
p< 0.01) also extended the incubation period that mice is added foot reaction, there is certain analgesic activity, but its analgesic effect and model group there was no significant difference.The results are shown in Table 3.
Table 2 mice lick foot response latency timetable (
)
Note: with model group comparison, *
p< 0.05, * *
p< 0.01.
the therapeutical effect of embodiment 9 Chinese medicine composition of the present invention to chronic prostatitis rat model
60 of male Wistar rat, are divided into model group, Western medicine (indometacin) matched group, Chinese medicine composition group of the present invention (high dose group, middle dosage group, low dose group), normal group at random.Except normal group, the method for totally 50 employing escherichia coli injection of prostate is made bacterial prostatitis rat model.High, normal, basic group of difference gavage of Chinese medicine composition of the present invention is according to the embodiment of the present invention 1 preparation Chinese medicine composition suspension of the present invention, high, normal, basic group of 3ml/d(Chinese medicine containing crude drug amount, be respectively 5g/ml, 2g/ml, 0.5g/ml), western medicine group gavage indometacin solution 3ml/d(content of dispersion 0.4mg/ml) model group, Normal group gavage normal saline.Gavage 30 days is put to death afterwards, the separated prostata tissue parallel pathologic finding of weighing.
Model rat prostate weight in wet base meansigma methods after table 3 traditional Chinese medicine composition for treating of the present invention
With model control group comparison,
p< 0.05; With model control group comparison,
p< 0.01;
With positive controls comparison,
p< 0.05; With positive controls comparison,
p< 0.01.
the prostatitic clinical data of embodiment 10 traditional Chinese medicine composition for treating of the present invention
1, physical data: selected 360 routine patients, are divided into treatment group and matched group, treatment group 180 examples, 25～60 years old age, average 43.2 years old at random; The course of disease 10 months～9 years, average 4.5 years; Married 60 examples; Matched group 180 examples, 23～55 years old age, average 40.1 years old; The course of disease 5 months～10 years, average 5.0 years; Married 65 examples; In above patient's symptom: urethral symptom refer to frequent micturition, urgent micturition, dysurea and the heeltap not to the utmost, drip after urine white; Local distending pain refers to perineal position distending pain or companion's lumbago and backache; General Symptoms finger is dizzy, weak, the symptoms such as insomnia.Two groups of cases, all through the super inspection of body of prostate B, are used the EUB-26 of Hitachi type diasonograph, and result all cases all has echo change, skewness, and edge is irregular, prompting chronic prostatitis, all cases per rectum refers to inspection, all points out chronic prostatitis; Between two groups, age, the state of an illness, the course of disease, little etc. situation difference, has comparability.
2, diagnostic criteria: with reference to " San circle whole nation combination of Chinese and Western medicine andropathy scientific seminar " agreed standard in 1993, according to patient's medical history, clinical symptoms, prostate palpation, prostate, press 3 of hydraulic fluid (EPS) microscopies, possessing 2 persons can make a definite diagnosis.Clinical symptoms: (1) paruria: urethral orifice adularescent mucoid secretions when frequent micturition, urgent micturition, dysurea, dribble of urine, urine end or stool, urethra scorching hot, scratchy and urinate not smooth (possessing more than 3); (2) local pain: perineum genital area, lower abdomen suprapubic region, lumbosacral region (at least one position continues more than 3 months).Prostate palpation (anus refers to inspection): Prostatic Surface is uneven, or asymmetric, and quality soft or hard is uneven, maybe can touch inflammatory tubercle, has local tenderness.Prostate is pressed hydraulic fluid (EPS) microscopy: every high power field leukocyte surpasses more than 10, and lecithin reduces or disappears.
3, Therapeutic Method: treatment group orally uses Chinese medicinal composition capsules agent of the present invention (preparing by the embodiment of the present invention 1), takes medicine once every day, and taking dose is 3g crude drug amount/d.Matched group: 200 milligrams of oral hydrochloride levofloxacin tablets, every day 2 times; 2 milligrams of terazosin sheets, 1 time every night, respectively treat 3 courses for the treatment of for two groups.
4, criterion of therapeutical effect: according to relevant chronic prostatitis criterion of therapeutical effect evaluation in < < disease clinical diagnosis and criterion of therapeutical effect > >, cure: transference cure, 3 massage liquid inspections are all normal, and B surpasses and digital rectal examination normal; Take a turn for the better: symptom is improved, massage liquid checks 10/HP of leukocyte <, 10/HP of lecithin >, and pyocyte disappears, and B surpasses and digital rectal examination shows that slight inflammatory changes; Invalid: treatment before and after symptom, check unchanged.
Table 4 treatment group and treatment of control group result synopsis
Treatment group is compared matched group and is had higher cure rate and improvement rate, thinks thus, and Drug therapy prostatitis of the present invention has good effect, and observes through the treatment of month, takes medicine of the present invention and does not occur any toxic and side effects.
Claims (5)
1. the prostatitic Chinese medicine composition for the treatment of, is characterized in that being made by the raw material of following weight portion: Rhizoma Corydalis 10-12 part, Cortex Cinnamomi 5-8 part, Herba Epimedii 6-9 part, Rhizoma dioscoreae 3-5 part, Radix Achyranthis Bidentatae 10-12 part, Semen Cuscutae 10-12 part, Radix Polygalae 3-5 part, Pericarpium Citri Reticulatae 3-5 part, Radix Salviae Miltiorrhizae 10-12 part, Flos Lonicerae 8-10 part, Rhizoma Polygoni Cuspidati 6-9 part, Polyalthia nemoralis A. D C. 10-12 part, Radix Angelicae Dahuricae 10-12 part, Radix Codonopsis 10-12 part, Rhizoma Cyperi 12-15 part, Radix Et Caulis Acanthopanacis Senticosi 9-12 part.
2. the prostatitic Chinese medicine composition for the treatment of as claimed in claim 1, is characterized in that: described Chinese medicine composition also contains Radix Glycyrrhizae 5-8 part and Fructus Ligustri Lucidi 12-15 part.
3. the prostatitic Chinese medicine composition for the treatment of as claimed in claim 1 or 2, is characterized in that: described Chinese medicine composition is powder, water preparation, tablet or capsule.
4. the preparation method of the prostatitic Chinese medicine composition for the treatment of as claimed in claim 1 or 2, it is characterized in that comprising following processing step: get traditional Chinese medicinal material raw materials and be broken into coarse powder, according to 4～9 times of coarse powder gross weight, adding volumetric concentration is 40%～95% alcoholic solution, reflux, extract, three times, return time is 2～5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
5. the Chinese medicine composition described in claim 1 or 2 is treated the purposes in prostatitis medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310569659.4A CN103599323B (en) | 2013-11-13 | 2013-11-13 | Traditional Chinese medicinal composition for treating prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310569659.4A CN103599323B (en) | 2013-11-13 | 2013-11-13 | Traditional Chinese medicinal composition for treating prostatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599323A true CN103599323A (en) | 2014-02-26 |
| CN103599323B CN103599323B (en) | 2015-05-27 |
Family
ID=50117629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310569659.4A Active CN103599323B (en) | 2013-11-13 | 2013-11-13 | Traditional Chinese medicinal composition for treating prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599323B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103920097A (en) * | 2014-04-29 | 2014-07-16 | 杨明 | Pharmaceutical composition for treating chronic prostatitis |
| CN104435716A (en) * | 2014-12-22 | 2015-03-25 | 周连才 | Traditional Chinese medicine composition for treating chronic bacterial prostatitis combined immunosuppression |
| CN104547624A (en) * | 2015-02-03 | 2015-04-29 | 赵兴武 | Traditional Chinese medicine composition for treating prostatodynia |
| CN105250950A (en) * | 2015-10-13 | 2016-01-20 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating bacterial prostatitis with antibiotic resistance |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660404A (en) * | 2005-01-19 | 2005-08-31 | 雷小平 | Health product of preserving health, invigorating the kidney and supporting yang for male |
| CN1753682A (en) * | 2003-01-16 | 2006-03-29 | 利盛私人有限公司 | The herbal-composition that is used for prostatosis |
-
2013
- 2013-11-13 CN CN201310569659.4A patent/CN103599323B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753682A (en) * | 2003-01-16 | 2006-03-29 | 利盛私人有限公司 | The herbal-composition that is used for prostatosis |
| CN1660404A (en) * | 2005-01-19 | 2005-08-31 | 雷小平 | Health product of preserving health, invigorating the kidney and supporting yang for male |
Non-Patent Citations (1)
| Title |
|---|
| 容红兵: "中西医结合治疗慢性细菌性前列腺炎45例", 《河南中医》, vol. 27, no. 08, 31 August 2007 (2007-08-31) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103920097A (en) * | 2014-04-29 | 2014-07-16 | 杨明 | Pharmaceutical composition for treating chronic prostatitis |
| CN104435716A (en) * | 2014-12-22 | 2015-03-25 | 周连才 | Traditional Chinese medicine composition for treating chronic bacterial prostatitis combined immunosuppression |
| CN104547624A (en) * | 2015-02-03 | 2015-04-29 | 赵兴武 | Traditional Chinese medicine composition for treating prostatodynia |
| CN105250950A (en) * | 2015-10-13 | 2016-01-20 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating bacterial prostatitis with antibiotic resistance |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599323B (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526634B (en) | Traditional Chinese medicine preparation for curing hyperplasia of mammary glands | |
| CN101234146B (en) | Traditional Chinese medicine preparation for treating urinary system affection and preparation thereof | |
| CN103599323B (en) | Traditional Chinese medicinal composition for treating prostatitis | |
| CN103830686B (en) | A kind of Chinese medicine composition for the treatment of hemorrhoid and uses thereof | |
| Liu et al. | Applications and therapeutic actions of complementary and alternative medicine for women with genital infection | |
| CN101385843B (en) | Nano medicine magnet therapy plaster for relieving the swelling and easing pain | |
| CN103536742B (en) | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof | |
| CN102908579B (en) | Traditional Chinese medicine preparation for treating gynecological diseases, liver diseases and prostatitis and preparation method of traditional Chinese medicine preparation | |
| CN102579999B (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN103599286A (en) | Traditional Chinese medicine composition for treating fibroid | |
| CN103705846B (en) | The Chinese medicine preparation for the treatment of ovarian cyst | |
| CN101130052A (en) | Traditional Chinese medicine for treating postpartum arthralgia | |
| CN103446500B (en) | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction | |
| CN104547688A (en) | Use of traditional Chinese medicine composition in preparation of medicine for treating haemorrhoids | |
| CN104435716A (en) | Traditional Chinese medicine composition for treating chronic bacterial prostatitis combined immunosuppression | |
| CN103585545B (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN100542591C (en) | The agent of a kind of treatment damp heat type chronic prostatitis herbal enema | |
| CN104274664A (en) | Traditional Chinese medicine composition for treating prostatitis by umbilical applied administration and preparation method thereof | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN102698126B (en) | Traditional Chinese medicine compound having effect of treating prostatitis and preparation method thereof | |
| CN103142710B (en) | Chinese medicinal composition for treating chronic prostatitis | |
| CN104644769A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatitis | |
| CN102580005A (en) | Zhuang ethnic group medical secret recipe for treatment of prostatitis | |
| CN103989791B (en) | A kind of compound Chinese medicinal preparation for the treatment of chronic prostatitis | |
| CN106619870A (en) | Composition for treating digestive system neoplasms, and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Jianming Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XUEJIAN TO: WANG JIANMING |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WU QIONG Free format text: FORMER OWNER: CUI HEFANG Effective date: 20150629 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150629 Address after: 226400 Jiangsu County of Rudong province juegang Tak District No. 13 Patentee after: Wu Qiong Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Patentee before: Cui Hefang |